• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

自然衰减的免疫力和疫苗诱导的免疫力下降导致再次感染 SARS-CoV-2 奥密克戎变异株。

Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant.

机构信息

Indian Council of Medical Research-National Institute of Virology, Pune, India.

出版信息

Hum Vaccin Immunother. 2022 Nov 30;18(6):2127289. doi: 10.1080/21645515.2022.2127289. Epub 2022 Sep 28.

DOI:10.1080/21645515.2022.2127289
PMID:36170667
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9746465/
Abstract

We have investigated six COVID-19 recovered cases with two doses of Covishield vaccination followed by reinfection. The primary SARS-CoV-2 infection found to occur with B.1 and reinfection with Omicron BA.1 and BA.2 variants. The genomic characterization and duration between two infections confirms these cases as SARS-CoV-2 reinfection. The immune response determined at different time intervals demonstrated boost post two dose vaccination, decline in pre-reinfection sera post 7 months and rise post reinfection. In conclusion, it was observed that these cases got SARS-CoV-2 reinfection with declined hybrid immunity acquired from primary infection and two dose covishield vaccination. This findings suggests the need to protect the community through booster dose of vaccination and prevent further infections following personal hygiene and non-pharmaceutical interventions.

摘要

我们研究了 6 例 COVID-19 康复病例，这些病例均接种了两剂 Covishield 疫苗，随后再次感染。最初的 SARS-CoV-2 感染被发现与 B.1 有关，而再次感染则与 Omicron BA.1 和 BA.2 变体有关。基因组特征和两次感染之间的时间间隔证实了这些病例是 SARS-CoV-2 的再次感染。在不同时间间隔测定的免疫反应显示，两剂疫苗接种后出现增强，7 个月后再次感染前血清中下降，再次感染后上升。总之，观察到这些病例因从初次感染和两剂 Covishield 疫苗获得的混合免疫力下降而再次感染 SARS-CoV-2。这些发现表明，需要通过加强疫苗接种来保护社区，并在个人卫生和非药物干预措施之后防止进一步感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fef/9746465/580651fc2701/KHVI_A_2127289_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fef/9746465/580651fc2701/KHVI_A_2127289_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fef/9746465/580651fc2701/KHVI_A_2127289_F0001_OC.jpg

相似文献

1
Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant.自然衰减的免疫力和疫苗诱导的免疫力下降导致再次感染 SARS-CoV-2 奥密克戎变异株。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2127289. doi: 10.1080/21645515.2022.2127289. Epub 2022 Sep 28.
2
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.接种疫苗后 6 个月，由疫苗单独或 SARS-CoV-2 感染加疫苗（混合免疫）诱导的抗体对奥密克戎（B.1.1.529）变异株的中和效果不佳。
EBioMedicine. 2022 Apr;78:103938. doi: 10.1016/j.ebiom.2022.103938. Epub 2022 Mar 16.
3
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.医护人员中，mRNA 疫苗接种与未接种者，初次感染奥密克戎（B.1.1.529）BA.1 或 前奥密克戎 SARS-CoV-2 对 BA.2 再感染的保护作用：一项病例对照研究。
Lancet Infect Dis. 2023 Jan;23(1):45-55. doi: 10.1016/S1473-3099(22)00578-3. Epub 2022 Sep 21.
4
Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.针对 SARS-CoV-2 奥密克戎变异株的中和抗体反应：接种 ChAdOx1 nCoV-19 或 BBV152 两剂和三剂疫苗后 6 个月。
Indian J Med Res. 2024 Feb 1;159(2):223-231. doi: 10.4103/ijmr.ijmr_948_23. Epub 2024 Apr 4.
5
Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.疫苗接种状态、主要变异株和既往感染后时间对 2020 年 2 月至 2022 年 2 月意大利雷焦艾米利亚省 SARS-CoV-2 再感染风险的影响：一项队列研究。
Euro Surveill. 2023 Mar;28(13). doi: 10.2807/1560-7917.ES.2023.28.13.2200494.
6
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation.儿童和青少年既往感染 SARS-CoV-2 后和单次接种 BNT162b2 疫苗对再感染的混合免疫：一项目标试验模拟。
Lancet Microbe. 2023 Jul;4(7):e495-e505. doi: 10.1016/S2666-5247(23)00103-9. Epub 2023 Apr 14.
7
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.先前感染 SARS-CoV-2 和混合免疫对奥密克戎变异株和重症疾病的保护效力：系统评价和荟萃回归分析。
Lancet Infect Dis. 2023 May;23(5):556-567. doi: 10.1016/S1473-3099(22)00801-5. Epub 2023 Jan 18.
8
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.奥密克戎变异株与新冠前变异株相比，既往感染 SARS-CoV-2 在预防再感染和 COVID-19 严重并发症方面的作用：系统评价。
BMC Infect Dis. 2023 Jun 26;23(1):432. doi: 10.1186/s12879-023-08328-3.
9
SARS-CoV-2 immune response and reinfection in vaccinated Maya and mestizo in Southeast of Mexico.墨西哥东南部接种疫苗的玛雅人和梅斯蒂索人的 SARS-CoV-2 免疫反应和再感染。
Salud Publica Mex. 2023 Dec 8;66(1, ene-feb):14-16. doi: 10.21149/15186.
10
Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.在墨西哥奥密克戎变异株占主导地位期间，混合免疫对 SARS-CoV-2 再感染和重症 COVID-19 的保护作用。
Front Public Health. 2023 Apr 4;11:1146059. doi: 10.3389/fpubh.2023.1146059. eCollection 2023.

引用本文的文献

1
Self-Reported Long COVID and Its Impact on COVID-19-Related Worries and Behaviors After Lifting the COVID-19 Restrictions in China.在中国解除新冠疫情限制措施后，自我报告的长期新冠症状及其对与新冠疫情相关的担忧和行为的影响。
Healthcare (Basel). 2025 Jan 29;13(3):262. doi: 10.3390/healthcare13030262.
2
A mini review of reinfection with the SARS-CoV-2 Omicron variant.严重急性呼吸综合征冠状病毒2型奥密克戎变种再感染的小型综述。
Health Sci Rep. 2024 Apr 10;7(4):e2016. doi: 10.1002/hsr2.2016. eCollection 2024 Apr.
3
In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-Protein.

本文引用的文献

1
SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report.伊拉克一名医护人员出现严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗突破性再感染：病例报告
Hum Vaccin Immunother. 2022 Nov 30;18(5):2055947. doi: 10.1080/21645515.2022.2055947. Epub 2022 Apr 13.
2
Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2.对 SARS-CoV-2 的核衣壳蛋白和刺突蛋白受体结合域的抗体进行纵向临床血清学分析。
Int J Infect Dis. 2021 Nov;112:103-110. doi: 10.1016/j.ijid.2021.09.024. Epub 2021 Sep 17.
3
Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity.
使用工程化 ACE-2 小蛋白检测患者血清中 SARS-CoV-2 中和抗体的体外诊断检测方法。
Viruses. 2022 Dec 18;14(12):2823. doi: 10.3390/v14122823.
2019冠状病毒病再感染、复发及PCR再阳性的定义。
Clin Microbiol Infect. 2021 Mar;27(3):315-318. doi: 10.1016/j.cmi.2020.11.028. Epub 2020 Dec 5.
4
Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.COVID-19 患者体内针对 SARS-CoV-2 的中和抗体反应。
Indian J Med Res. 2020;152(1 & 2):82-87. doi: 10.4103/ijmr.IJMR_2382_20.
5
Development of transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India.转录RNA作为印度SARS-CoV-2实验室诊断阳性对照的开发。
Indian J Med Res. 2020;151(2 & 3):251-254. doi: 10.4103/ijmr.IJMR_671_20.
6
Complete genome sequencing of Kaisodi virus isolated from ticks in India belonging to Phlebovirus genus, family Phenuiviridae.从印度蜱中分离到的属于 Phlebovirus 属、Phenuiviridae 科的 Kaisodi 病毒的全基因组测序。
Ticks Tick Borne Dis. 2019 Jan;10(1):23-33. doi: 10.1016/j.ttbdis.2018.08.012. Epub 2018 Aug 28.